Lumenis Ophthalmology

Q: If it is clinically equivalent to ALT, why is SLT a better option?

A: For open angle glaucoma patients, SLT is as equally effective in reducing and maintaining low intraocular pressure (IOP) as ALT. However, the Selecta II does not cause a burn in the trabecular meshwork like ALT, which is causing physicians to reevaluate how laser treatment fits into the glaucoma therapy hierarchy.

Q: How does SLT work?

A: SLT utilizes a 3-nanosecond high-energy beam of light to induce the same cell replacement mechanism as ALT, but without the burn. SLT does this by delivering just enough energy to the trabecular meshwork to target specific melanin-rich cells for replacement, without disruption to the surrounding tissue and structure of the trabecular meshwork. It is simply more precise; one ALT laser shot carries 6,000 times the energy of one SLT "drop of light" which accomplishes the same effect on the trabecular meshwork.

Q: Can existing ophthalmic lasers be used to perform SLT?

A: No, the Selecta II specifications are unique and no other laser can be used to perform this treatment. Nd:YAG lasers commonly used for treating a cataract surgery complication known as secondary cataract are equipped with an inappropriate wavelength and spot size and can actually do serious harm if directed at the trabecular meshwork. Argon and similar lasers used for ALT and retinal photocoagulation are not equipped with the Q-switch necessary to achieve a 3 nanosecond pulse and also do not have high enough peak power to effect a result on the trabecular meshwork without causing a burn.

Q: Will Lumenis see competitors enter the US market?

A: Lumenis has an exclusive license to the "Latina Patent" for the technology and method of performing SLT from the Massachusetts General Hospital. Our license ensures that Lumenis will be the only company to develop and market the relevant technology for performing SLT in the United States.

Q: Is SLT too new to be widely accepted and used by ophthalmologists? Is it safe?

A: Clinical work has been ongoing in the United States for five years leading up to the recent FDA clearance. In addition, thousands of patients have been treated at international sites with consistently good results, including many in Europe and Japan where SLT has been approved and in use for several years. Contrary to other products that are often rushed to market, SLT is being introduced in the United States with solid scientific proof of its mechanisms of action, its effectiveness in lowering and maintaining low IOP, and its safety.

Q: Where can I find more information on ophthalmic conditions and treatments?

A: Please visit our helpful Related Links page.

product family

Email Alerts
Sign up to receive the latest product, training and update information.


Zip Code  

©2016 Lumenis Ophthalmology | Terms of Use | Legal Notice | Privacy Statement | Trademarks | Corporate